Valion Bio, Inc.: Valion Bio Announces Reverse Stock Split

Valion Bio, Inc. (Nasdaq:VBIO) announced a 1-for-25 reverse stock split to comply with Nasdaq's minimum bid price requirement. The split, approved by shareholders, will take effect on August 31, 2026, and trading will resume under the same symbol. The company aims to regain compliance and maintain its Nasdaq listing.

Original reporting
Published Aug 27, 2026, 1:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 27, 2026, 1:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$VBIO
Neutral
high confidence
Mentioned
$VBIO
Relevance
6/10
alphai data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$VBIONeutralMed
01

Why it matters

The split aims to restore compliance, but may not address fundamental business challenges.

02

Market read

Corporate action for a microcap biotech; relevance mainly to shareholders and short-term traders.

03

What to watch

Impact on existing warrants, options, and preferred stock conversions could affect dilution and valuation.

Relevance 6/10Novelty 7/10Timing: effective Aug 31 2026

Background

Valion Bio is a Nasdaq-listed biotech developing TLR5 agonists, currently below $1 bid price for 30 days.

Company-level read

Ticker impact

$VBIONeutralHigh confidence
Context

Valion Bio announced a 1-for-25 reverse stock split to regain Nasdaq compliance.

Expected impact

Short-term volatility expected; price may rise to meet $1 minimum, then stabilize.

Evidence & confidence

Corporate actions like reverse splits often cause immediate price adjustments as investors react to compliance news.

Market effects

May signal tightening Nasdaq compliance enforcement for biotech microcaps.

Limited to US Nasdaq-listed biotech sector.

Low; primarily affects Valion Bio shareholders.

Counterpoint

Reverse splits can be a red flag of underlying weakness; investors may short ahead of potential delisting.

Key entities

  • Valion Bio, Inc.

    Nasdaq-listed biotech announcing reverse split.

Related articles

$VBIOMed

Valion Bio, Inc.: Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase

Valion Bio (Nasdaq:VBIO) said Ukraine’s Ministry of Health accepted its Entolimod dossier for formal review on July 22, 2026, and started a technical assessment with questions on physicochemical characterization for a potential stockpiling supply. The company expects a possible decision as early as Q4 2026, which could enable national registration and potential future government procurement, though no deal is signed.

$VBIOMed

Valion Bio, Inc.: Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury

Valion Bio (Nasdaq:VBIO) said AFRRI, under a contract with NIAID, is running U.S. government-funded studies of Entolimod for radiation-induced GI injury. A safety study is planned to start this week, followed by a therapeutic study with top-line data expected in early fall. The program aims to assess survival and GI recovery after lethal radiation doses.

$BAHighAI 9/10

Air Force awards Boeing $131 billion ceiling contract for F-15 production, modernization

The U.S. Air Force awarded Boeing a $131.23 billion contract for F-15 production, modernization, and sustainment through 2037. The contract includes options for foreign military sales to several countries. Initial funding is $343,740 for fiscal 2026. Boeing will perform the work in St. Louis. The contract does not guarantee full spending and includes no immediate jet orders.

$AECMed

SW US: Anfield wants $50M for Utah mill

Anfield Energy (TSXV, Nasdaq: AEC) plans to raise $50M to refurbish Utah's Shootaring Canyon mill, aiming for a 2028 reopening. The mill will process uranium and vanadium, reducing U.S. reliance on imports. Capital expenditures are estimated at $80.1M, with flexibility in financing options. The company expects a mill licence by late 2024 or early 2027, unlocking financing and construction. An updated PEA forecasts significant after-tax NPV and IRR, with production from Velvet-Wood and Slick Rock

$CFLowAI 8/10

Construction begins on Louisiana clean ammonia plant

CF Industries, JERA, and Mitsui began constructing a $3.7B low-carbon ammonia plant in Louisiana, producing 1.4M tons annually. The plant will sequester 98% of CO₂ emissions, with CF Industries owning 40%. Ammonia will supply U.S. farmers and Asian power plants, creating 3,900 jobs during construction and 100 permanent roles. Production is expected to start in 2029, according to the companies.